Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

Michael J. Overman, MD
Published: Wednesday, Jun 15, 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC).

Interim results of the CheckMate-142 study show that among patients who received single-agent nivolumab, median progression-free survival (PFS) was approximately 6 months. Additionally, Overman explains, PFS at 12 months was approximately 45%.

In the combination cohort of nivolumab/ipilimumab, preliminary findings show an 80% reduction in tumor size, while monotherapy with ipilimumab demonstrated a 55% reduction in tumor size. However, longer follow-up is needed in the combination cohort to confirm these findings, he adds.
Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC).

Interim results of the CheckMate-142 study show that among patients who received single-agent nivolumab, median progression-free survival (PFS) was approximately 6 months. Additionally, Overman explains, PFS at 12 months was approximately 45%.

In the combination cohort of nivolumab/ipilimumab, preliminary findings show an 80% reduction in tumor size, while monotherapy with ipilimumab demonstrated a 55% reduction in tumor size. However, longer follow-up is needed in the combination cohort to confirm these findings, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x